The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2019 | Regulatory hurdles in CAR T-cell therapy roll-out
Despite having demonstrated promising response rates in treated patients, CAR T-cell therapies are faced with regulatory issues. Bruce Levine, PhD, from the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, discusses how the therapy’s reliance on genetic modification, viral production, and cell expansion can pose challenges to the clinical application of CAR T-cells. This video was recorded at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.
